Sammenligning af Ivonescimab og pembrolizumab ved NSCLC
Dette er en AI opsummering af abstractet til “Comparing the Efficacy and Safety of Ivonescimab with Pembrolizumab in PD-L1-Positive Advanced Non-Small Cell Lung Cancer: HARMONi-2 Phase 3 Trial”.
Ivonescimab significantly improved progression-free survival compared with pembrolizumab in untreated patients with advanced PD-L1 positive non-small cell lung cancer. The study was published in The Lancet.
HARMONi-2 was a phase 3 trial comparing ivonescimab with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer. The interim analysis showed a longer median PFS with ivonescimab (11·1 months) compared to pembrolizumab (5·8 months).
#Klinisk onkologi
Læs orginal abstract og artikel via Pubmed
*Disclaimer: AI baseret tekst, der har taget udgangspunkt i artiklen abstract. Teksten er derfor ikke egnet til at danne grundlag for fx. kliniske beslutninger. Tanken er snarere at give læseren lyst til at gå til kilde-teksten, og blive klogere.
